Evidence map›Paper›PMID 30992551›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2019

Aberrant DNA methylation as a diagnostic biomarker of diabetic embryopathy.

Katharina V Schulze, Amit Bhatt, Mahshid S Azamian, Nathan C Sundgren, Gladys E Zapata, Patricia Hernandez, Karin Fox, Jeffrey R Kaiser, John W Belmont, Neil A Hanchard

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Syndromic variants of biliary atresia.World journal of pediatric surgery · 2025
    Review
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Katharina V SchulzeDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8268-5565
Amit BhattDepartment of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Mahshid S AzamianDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Nathan C SundgrenDepartment of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Gladys E ZapataDepartment of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Patricia HernandezDepartment of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Karin FoxDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Jeffrey R KaiserDepartment of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
John W BelmontDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Neil A HanchardDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA. hanchard@bcm.edu.
Baylor College of Medicine · US

Funding

PROGRAM IN HUMAN MOLECULAR GENETICST32GM008307 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI SHAULSKY, GAD · 1990 to 2020
$6.6M
NIGMS NIH HHS T32GM008307
6 · The paper itself

Abstract

purposeMaternal diabetes is a known teratogen that can cause a wide spectrum of birth defects, collectively referred to as diabetic embryopathy (DE). However, the pathogenic mechanisms underlying DE remain uncertain and there are no definitive tests to establish the diagnosis. Here, we explore the potential of DNA methylation as a diagnostic biomarker for DE and to inform disease pathogenesis.

methodsBisulfite sequencing was used to identify gene regions with differential methylation between DE neonates and healthy infants born with or without prenatal exposure to maternal diabetes, and to investigate the role of allele-specific methylation at implicated sites.

resultsWe identified a methylation signature consisting of 237 differentially methylated loci that distinguished infants with DE from control infants. These loci were found proximal to genes associated with Mendelian syndromes that overlap the DE phenotype (e.g., CACNA1C, TRIO, ANKRD11) or genes known to influence embryonic development (e.g., BRAX1, RASA3). Further, we identified allele-specific methylation (ASM) at 11 of these loci, within which 61.5% of ASM single-nucleotide variants are known expression quantitative trait loci (eQTLs).

conclusionsOur study suggests a role for aberrant DNA methylation and cis-sequence variation in the pathogenesis of DE and highlights the diagnostic potential of DNA methylation for teratogenic birth defects.

Indexed as

AllelesBiomarkersCpG IslandsDiabetes ComplicationsDiabetes MellitusDNA MethylationFemaleFetal DiseasesGenome-Wide Association StudyHumansInfantInfant, NewbornPolymorphism, Single NucleotidePregnancyQuantitative Trait LociBiomarkersallele-specific methylationbisulfite sequencingdiabetic embryopathyinfant of a diabetic motherteratogens

Identifiers

PMID30992551
OpenAlexW2937711210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.